Verition Fund Management’s Ocular Therapeutix OCUL Stock Holding History

Verition Fund Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.47M	Buy	527,338 +355,732	+207%	+$3.39M	0.03%	631
2025 Q4	$2.08M	Buy	171,606 +5,573	+3%	+$67.7K	0.01%	1580
2025 Q3	$1.94M	Buy	166,033 +17,431	+12%	+$208K	0.01%	2010
2025 Q2	$1.38M	Buy	148,602 +78,172	+111%	+$612K	0.01%	2228
2025 Q1	$516K	Buy	+70,430	New	+$541K	﹤0.01%	2571
2024 Q4	–	Sell	-62,501	Closed	-$544K	–	3434
2024 Q3	$544K	Buy	+62,501	New	+$515K	﹤0.01%	2268
2023 Q3	–	Sell	-54,950	Closed	-$284K	–	2578
2023 Q2	$284K	Buy	+54,950	New	+$327K	﹤0.01%	1597
2023 Q1	–	Sell	-17,502	Closed	-$49.2K	–	2443
2022 Q4	$49.2K	Buy	17,502 +7,273	+71%	+$24.1K	﹤0.01%	1890
2022 Q3	$42K	Hold	10,229	–	–	﹤0.01%	2705
2022 Q2	$41K	Buy	10,229 +229	+2%	+$865	﹤0.01%	2169
2022 Q1	$50K	Hold	10,000	–	–	﹤0.01%	2489
2021 Q4	$70K	Buy	+10,000	New	+$77.7K	﹤0.01%	2378

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Verition Fund Management's OCUL Position: Q1 2026 in Review

Verition Fund Management increased its Ocular Therapeutix (OCUL) stake by 207% in Q1 2026, buying an estimated $3.39M and bringing the position to 527,338 shares worth $4.47M. The position accounts for 0.03% of the portfolio, ranked #631.

Verition Fund Management first reported a position in OCUL in Q4 2021 and has held it in 12 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Verition Fund Management held 527,338 shares of Ocular Therapeutix worth $4.47M as of Q1 2026.
Verition Fund Management bought 355,732 Ocular Therapeutix shares in Q1 2026, an estimated $3.39M.
Ocular Therapeutix made up 0.03% of Verition Fund Management's portfolio in Q1 2026, its #631 holding.
Verition Fund Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 12 quarters since.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.